NIOX GroupCSSPF 77 Earnings Yield (Joel Greenblatt) % is 4.33% as of Dec. 2025. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 855 Medical Devices & Instruments companies, NIOX Group ranks better than 71.58% on this metric.
NIOX Group's Enterprise Value for the quarter that ended in Dec. 2025 was $359.16 Mil.
NIOX Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $15.10 Mil. NIOX Group's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 4.33%.
The historical rank and industry rank for NIOX Group's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CSSPF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2519.85 Med: -14.11 Max: 7.13
Current: 4.96
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of NIOX Group was 7.13%. The lowest was -2519.85%. And the median was -14.11%.
CSSPF's Earnings Yield (Joel Greenblatt) % is ranked better than 71.58% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.76
vs CSSPF: 4.96
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. NIOX Group's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
NIOX Group (OTCPK:CSSPF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
NIOX Group Earnings Yield (Joel Greenblatt) % Related Terms
NIOX Group Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for NIOX Group's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group Earnings Yield (Joel Greenblatt) % Chart
For the Medical Devices subindustry, NIOX Group's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where NIOX Group's Earnings Yield (Joel Greenblatt) % falls into.
NIOX Group Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
NIOX Groups Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 4.33% mean?
NIOX Group (CSSPF) has a Earnings Yield (Joel Greenblatt) % of 4.33% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on NIOX Group and its competitors. According to the industry distribution chart, NIOX Group ranks #243 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 28.4%.
Is NIOX Group's Earnings Yield (Joel Greenblatt) % too high?
NIOX Group's current Earnings Yield (Joel Greenblatt) % is 4.33%. The Medical Devices & Instruments industry median Earnings Yield (Joel Greenblatt) % is 0.76. NIOX Group's value of 4.33% is 469.7% above this industry median. Based on the distribution chart, NIOX Group ranks #243 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Earnings Yield (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #243 out of 855 companies for Earnings Yield (Joel Greenblatt) %. This puts NIOX Group in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.76. NIOX Group's value of 4.33% is 469.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.76, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Earnings Yield (Joel Greenblatt) % of 4.33% is 469.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Earnings Yield (Joel Greenblatt) % is 4.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.75 — trading 38% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 4.33% and 469.7% above the Medical Devices & Instruments industry median of 0.76. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Earnings Yield (Joel Greenblatt) % is 4.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 38% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Earnings Yield (Joel Greenblatt) %: 4.33%
GF Value™: $1.21 vs. price of $0.75 (38% below fair value)
Industry Position: 469.7% above the Medical Devices & Instruments median (#243 of 855)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
